Design of The Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) trial
Design of The Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) trial
复制标题
DOI：
10.1016/s0002-9149(01)01622-8
复制
发表时间：
2001-07-15
影响因子：
2.8
通讯作者：
Annex, BH
中科院分区：
文献类型：
--
作者：
Lederman, RJ;Tenaglia, AN;Annex, BH
应用重组成纤维细胞生长因子-2治疗间歇性跛行的血管生成(TRAFCKS)是一项大型、随机、安慰剂对照、动脉内注射重组成纤维细胞生长因子-2治疗间歇性跛行患者的方案寻找试验。本报告介绍了流量的主要设计注意事项和端点。
The Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) is a large, randomized, placebo-controlled, regimen-finding trial of intra-arterial recombinant fibroblast growth factor-2 in patients with intermittent claudication. This report describes the major design considerations and end points in TRAFFIC.